![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentre Treatment Protocol
|
|
|
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Brown Jr RS,1 Fried MW,2 Reddy KR,3 Soldevila-Pico C,4 Khemichian S,5 Darling J,2 Napoli AA,6 Anduze-Faris B,6 Kwo P7
1Weill Cornell Medical College, Center for Liver Disease, New York, NY, USA; 2University of North Carolina, Chapel Hill, NC, USA; 3Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 4Department of Medicine, University of Florida, Gainesville, FL, USA; 5Keck School of Medicine, University of Southern California, Los Angeles, CA, USA;
6Bristol-Myers Squibb, Plainsboro, NJ, USA; 7Indiana University, Indianapolis, IN, USA
![EASL1](../images/042116/042116-1/EASL1.gif)
![EASL2](../images/042116/042116-1/EASL2.gif)
![EASL3](../images/042116/042116-1/EASL3.gif)
![EASL4](../images/042116/042116-1/EASL4.gif)
![EASL5](../images/042116/042116-1/EASL5.gif)
![EASL6](../images/042116/042116-1/EASL6.gif)
![EASL7](../images/042116/042116-1/EASL7.gif)
![EASL8](../images/042116/042116-1/EASL8.gif)
![EASL9](../images/042116/042116-1/EASL9.gif)
![EASL10](../images/042116/042116-1/EASL10.gif)
![EASL11](../images/042116/042116-1/EASL11.gif)
![EASL12](../images/042116/042116-1/EASL12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|